Core Viewpoint - Taimei Medical Technology (02576) reported a decline in revenue for the first half of 2025, primarily due to a decrease in digital service income [1] Financial Performance - Revenue for the period was approximately 244 million yuan, representing a year-on-year decrease of 10.5% [1] - The loss attributable to the company's owners was 22.802 million yuan, which narrowed by 86.68% compared to the previous year [1] - Earnings per share were reported at a loss of 0.04 yuan [1] Revenue Breakdown - The decrease in revenue was mainly attributed to a decline in income from digital services [1]

Group 1 - The core viewpoint of the article is that Taimei Medical Technology (02576) reported a decline in revenue and a reduced loss for the first half of 2025 [1] Group 2 - The company's revenue for the first half of 2025 was approximately 244 million, representing a year-on-year decrease of 10.5% [1] - The loss attributable to the company's owners was 22.802 million, which narrowed by 86.68% year-on-year [1] - The loss per share was reported at 0.04 yuan [1] - The decrease in revenue was primarily attributed to a decline in digital service income [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Zhejiang Taimei Medical Technology Co., Ltd. 浙江太美醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2576） 截至2025年6月30日止六個月的中期業績公告 董事會謹此宣佈本集團截至2025年6月30日止六個月的未經審計合併中期業績連 同截至2024年6月30日止六個月的比較數字。 財務摘要 | | | 截至6月30日止六個月 | | | | | --- | --- | --- | --- | --- | --- | | | | 2025年 | 2024年 | | 同比變動 | | | 人民幣千元 | 收入百分比 | 人民幣千元 | 收入百分比 | (%) | | 收入 | 244,221 | 100.0 | 272,784 | 100.0 | -10.5 | | 毛利 | 100,188 | 41.0 | 110,944 | ...

最近一个月来，太美医疗科技累计涨幅31.65%，今年来累计涨幅9.81%，跑输恒生指数25.51%的涨幅。 财务数据显示，截至2024年12月31日，太美医疗科技实现营业总收入5.51亿元，同比减少3.84%；归母 净利润-2.15亿元，同比增长38.11%；毛利率40.81%，资产负债率22.02%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，软件服务行业市盈率（TTM）平均值为-23.05倍，行业中值-2.79倍。太美医疗科技市盈 率-11.43倍，行业排名第108位；其他京投交通科技（01522.HK）为4.82倍、禅游科技（02660.HK）为 5.51倍、自动系统（00771.HK）为5.92倍、博雅互动（00434.HK）为6.39倍、驴迹科技（01745.HK）为 6.5倍。 8月19日，截至港股收盘，恒生指数下跌0.21%，报25122.9点。太美医疗科技（02576.HK）收报5.24港 元/股，上涨11.49%，成交量54.44万股，成交额274.24万港元，振幅12.77%。 大事提醒 2025年8月28日，披露2025财年中报 （以上内容为金融界基于公开消息，由 ...

格隆汇7月25日丨太美医疗科技(02576.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议 （如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Zhejiang Taimei Medical Technology Co., Ltd. 於本公告日期，董事會由執行董事趙璐先生、馬東先生、張宏偉先生、陸一鳴先 生、黃玉飛先生及倪曉梅女士；及獨立非執行董事蔣驍博士、李治國博士及馮志 偉先生組成。 （股份代號：2576） 董事會會議日期 浙江太美醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）茲宣佈謹定於2025年8月28日（星期四）召開董事會會議， 以（其中包括）審議及通過本集團截至2025年6月30日止六個月之中期業績及其發 佈，以及審議派發中期股息之建議（如有）。 承董事會命 浙江太美醫療科技股份有限公司 董事長 趙璐先生 香港，2025年8月12日 浙江太美醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江太美醫療科技股份有限公司 (「本公司」) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02576 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 200,592,533 | RMB | | 1 RMB | | 200,592,533 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 200,592,533 | RMB | | 1 RMB | | 200,592,533 | | 2. 股份分類 | 普通股 | 股 ...

Group 1 - The company, Zhejiang Taimei Medical Technology Co., Ltd., announced a sudden change in its financial leadership, with CFO Jiang Chengwen resigning due to personal reasons and Wang Wei appointed as the new CFO [1] - Wang Wei, aged 36, has over ten years of experience in capital market transactions and has held various senior positions in financial institutions, including Credit Suisse and Huadeng Capital [2] - The company has reported continuous losses for 11 years since its establishment in 2013, with a revenue of 551 million yuan in 2024, a year-on-year decrease of 3.8%, and a net loss of 217 million yuan [3] Group 2 - The company's workforce has significantly reduced from 1,490 full-time employees at the end of 2021 to 627 by the end of 2024, indicating a nearly 60% reduction in staff [3] - Cost-cutting measures have led to a 40% decrease in employee welfare expenses, resulting in a gross margin increase of 9.6 percentage points to 40.8% in 2024 [3] - Despite the improvement in gross margin, the company's R&D investment has nearly halved, raising concerns about its long-term competitiveness in the market [3]

7月23日，截至港股收盘，恒生指数上涨1.62%，报25538.07点。太美医疗科技（02576.HK）收报4.7港 元/股，上涨11.64%，成交量68.28万股，成交额313.62万港元，振幅14.96%。 最近一个月来，太美医疗科技累计涨幅25.67%，今年来累计跌幅1.64%，跑输恒生指数25.27%的涨幅。 来源：金融界 行业估值方面，软件服务行业市盈率（TTM）平均值为-11.38倍，行业中值-3.05倍。太美医疗科技市盈 率-10.24倍，行业排名第109位；其他京投交通科技（01522.HK）为3.88倍、黄河实业（00318.HK）为 5.21倍、驴迹科技（01745.HK）为5.58倍、自动系统（00771.HK）为5.75倍、禅游科技（02660.HK）为 6.02倍。 资料显示，浙江太美医疗科技股份有限公司是中国医药及医疗器械研发和营销领域的数字化解决方案供 应商,市场份额为5.9%。公司为医药及医疗器械行业的产业链各方设计并提供专业的软件及数字化服 务。基于公司对医药及医疗器械的丰富经验和洞察,和对先进技术的组合运用,公司正在建设更完善的数 字基础设施,以加速医药及医疗器械的研发和营 ...

Core Viewpoint - The article highlights the evolution of Taimei Medical Technology from a SaaS tool provider to a comprehensive digital solution supplier in the clinical trial sector, emphasizing its role in driving AI-enabled advancements in the life sciences industry [2][3][4]. Company Development - Taimei Medical Technology has grown to serve over 1,400 pharmaceutical companies and CROs, including 21 of the top 25 global pharmaceutical companies and 90 of the top 100 Chinese innovative pharmaceutical companies [2]. - The company aims to create an "intelligent driving platform" for clinical trials, integrating AI to enhance efficiency and collaboration across the entire research process [4][5]. AI Integration - The introduction of the "Digital Employee" system allows AI agents to be embedded throughout the clinical research process, significantly improving efficiency and reducing error rates [4]. - Specific AI applications include iDM for data management, which increases database creation efficiency by 80% and reduces error rates by 50%, and iCTA for document management, which cuts attribute filling time by 70% [4]. Industry Context - The past decade has seen a significant rise in the approval of innovative drugs in China, with the number of Class 1 innovative drugs approved expected to reach 48 in 2024, over five times the number in 2018 [5][6]. - Taimei Medical Technology has partnered with major innovative pharmaceutical companies, evolving from a provider of efficiency tools to a central hub for intelligent collaboration [6][7]. Market Trends - Multinational pharmaceutical companies are increasing their R&D investments in China, recognizing its importance in global early-stage research [7]. - Local large pharmaceutical companies are transitioning towards innovation, reducing reliance on generic drugs and enhancing their competitive capabilities [7][8]. Future Outlook - Taimei Medical Technology plans to enhance service quality and accelerate its international expansion, aiming to grow alongside Chinese innovative pharmaceuticals [8].